Systematic mediastinal lymphadenectomy does not increase postoperative immune response after major lung resections.
OBJECTIVE
To assess the influence of mediastinal lymphadenectomy on postoperative concentration of interleukin 6 (IL-6) and interleukin 1 receptor antagonist (IL-1 ra) in serum, sputum, and pleural fluid, in patients operated upon due to lung cancer and benign pulmonary diseases.


METHODS
Thirty-three patients undergoing uncomplicated resections, including 23 with lung cancer and 10 with benign diseases, were analyzed. In patients with right lung cancer we performed a systematic lymphadenectomy, while in patients with left lung cancer systematic sampling was performed. Serum IL-6 and IL-1 ra concentration was measured before and after surgery, and on postoperative days 1, 3, and 7, as well as in sputum at the end of surgery and in pleural fluid on postoperative day 1, by ELISA test.


RESULTS
In 23 patients with cancer, 19.0+/-11.43 mediastinal lymph nodes were removed (in 11 patients with right lung cancer 27.6+/-7.6 and in 12 patients with left lung cancer 11.1+/-8.1). No differences were found in serum and sputum concentration of IL-6 and IL-1 ra between patients after right and left thoracotomy due to cancer and between patients with cancer and patients with benign diseases. Patients with cancer had a lower concentration of IL-1 ra in pleural fluid (median 16950, range 16050-45470.05 pg/ml) than patients with benign diseases (76665.6 pg/ml (range 53618-89617.9); p=0.0008). In 23 cancer patients a negative correlation between concentration of cytokines in pleural fluid and a number of mediastinal lymph nodes resected was observed (Spearman correlation coefficient for IL-6: r=-0.44, p=0.04; for IL-1 ra: r=-0.57, p=0.01). Such correlation was not observed for a number of positive N2 lymph nodes.


CONCLUSIONS
Systematic lymphadenectomy added to major lung resection does not increase postoperative humoral immune response in uncomplicated cases, as measured by levels of IL-6 and IL-1 ra in serum, pleural fluid, and sputum.
Szczesny
Tomasz Jarosław
TJ
Department of Thoracic Surgery, Regional Lung Diseases Hospital, Prabuty, Poland. szczesny@lungcancer.med.pl
Słotwiński
Robert
R
Szczygieł
Bruno
B
Stankiewicz
Aleksander
A
Zaleska
Marzanna
M
Kopacz
Maria
M
Olesińska-Grodź
Aleksandra
A
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000601:surgery; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008171:Lung Diseases / Q000276:immunology / Q000601:surgery; D008175:Lung Neoplasms / Q000276:immunology / Q000601:surgery*; D008197:Lymph Node Excision; D008297:Male; D008482:Mediastinum; D008875:Middle Aged; D010996:Pleural Effusion / Q000276:immunology; D011013:Pneumonectomy; D011184:Postoperative Period; D011446:Prospective Studies; D013183:Sputum / Q000276:immunology
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6